Cell Therapy News

Product attributes appeared associated with more potent and durable responses to axicabtagene ciloleucel among patients with follicular lymphoma, according to an analysis of the ZUMA-5 trial.

More than 80% of patients with heavily pretreated metastatic melanoma experienced tumor shrinkage after receiving the adoptive cell therapy lifileucel, according to results of a phase 2 study.

The FDA granted orphan drug designation to CYNK-001 for the treatment of malignant gliomas, according to the agent’s manufacturer.

Four of five patients with relapsed or refractory B-cell lymphoma demonstrated complete response to an investigational anti-CD19/CD20 chimeric antigen receptor T-cell therapy, according to early data from a phase 1 trial.

American Association for Cancer Research presented its AACR Team Science Award to the St. Baldrick’s Foundation-Stand Up To Cancer Pediatric Cancer Dream Team.

Although it took a bit longer than expected, the first FDA approval of a chimeric antigen receptor T-cell therapy for advanced multiple myeloma will have a major impact on clinical practice, according to experts.

Chimeric antigen receptor T-cell therapies demonstrated greater clinical effectiveness than standard care among patients with heavily pretreated multiple myeloma, according to a report by the Institute for Clinical and Economic Review.

The FDA cleared an investigational new drug application for ACLX-001, a chimeric antigen receptor T-cell therapy for adults with relapsed and refractory multiple myeloma, according to the agent’s manufacturer.

More than 80% of patients who responded to therapy with tabelecleucel for Epstein-Barr virus-driven post-transplant lymphoproliferative disease remained alive 2 years after initial treatment, study results showed.

Lisa M. Coussens, PhD, FAACR, has been elected president-elect of American Association for Cancer Research for the 2021-2022 term.